Chordoma Clinical Trial
Official title:
Hypoxia-PET and IMPT Dose Painting in Patients With Chordomas: A Pilot Study
Before radiation treatment is given to treat chordomas, CT and MRI scans are used to create a three dimensional picture of the tumor using x-rays. The CT and MRI scans are used to determine the size and location of the area that will receive radiation treatment. The purpose of this research study is to see if combining the images from the FMISO-PET scan and the CT and MRI scans in radiation treatment planning changes the size and location of the area that will receive radiation treatment when compared to planning the radiation treatment with CT and MRI scans alone.
- In this research study we are determining whether the positron emission tomography
(PET) investigation performed with the investigational radioactive substance FMISO can
show areas of tumor with lower oxygen levels. There is evidence that tumor with low
oxygen levels are more resistant to radiation therapy. CT and MRI scans are not able to
detect these oxygen levels in tumors.
- Participants will be asked to have the FMISO-PET/CT scan at 2 different times. It will
be performed 2 weeks before and 3 weeks after the participants first proton radiation
treatment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03955042 -
Pemetrexed for the Treatment of Chordoma
|
Phase 1 | |
| Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
| Active, not recruiting |
NCT00496119 -
Proton Beam Therapy for Chordoma Patients
|
Phase 2 | |
| Recruiting |
NCT06029218 -
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
|
N/A | |
| Completed |
NCT03595228 -
BN Brachyury and Radiation in Chordoma
|
Phase 2 | |
| Recruiting |
NCT06140732 -
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
|
Phase 2 | |
| Active, not recruiting |
NCT01175109 -
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
|
Phase 1 | |
| Completed |
NCT00150072 -
Efficacy and Safety of Imatinib in Chordoma
|
Phase 2 | |
| Terminated |
NCT00003926 -
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05041127 -
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
|
Phase 2 | |
| Recruiting |
NCT05861245 -
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
|
N/A | |
| Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
| Completed |
NCT02383498 -
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
|
Phase 2 | |
| Recruiting |
NCT03242382 -
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
|
Phase 2 | |
| Completed |
NCT02520128 -
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
|
N/A | |
| Recruiting |
NCT01567046 -
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
|
N/A | |
| Recruiting |
NCT02986516 -
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
|
N/A | |
| Completed |
NCT00919269 -
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
|
||
| Active, not recruiting |
NCT02989636 -
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
|
Phase 1 | |
| Active, not recruiting |
NCT03083678 -
Afatinib in Locally Advanced and Metastatic Chordoma
|
Phase 2 |